|
Location, Country
|
Ifakara, Tanzania
|
Navrongo, Ghana
|
Manhiça, Mozambique
|
Kumasi, Ghana
|
Lambaréné, Gabon
|
Tamale, Ghana
|
|
Reference
|
Schellenberg et al.
|
Chandramohan et al.
|
Macete et al.
|
Kobbe et al.
|
Grobusch et al.
|
Mockenhaupt et al.
|
|
|
Lancet 2001, 2005
|
BMJ 2005
|
JID 2006
|
CID 2007
|
JID 2007
|
AAC 2007
|
|
Primary outcome-protocol
|
Incidence of clinical malaria and severe anaemia episodes in each group by 12 months of age. The word “incidence” is not defined in the protocol
|
N/A
|
Incidence of first or only malaria episodes [sic] in each studycohort by 12 months of age
|
Rate of episodes of malaria and/or severe anaemia
|
Proportion of children between 3and 18 months of age with at least one episode of (1)anemia (Hb < 9g/dL) and (2) malaria (parasitemia with fever)
|
Incidence of clinical malaria, severe malaria, and hospital visits
|
|
Primary outcome-manuscript
|
First or only episode of clinical malaria and severe anaemia in the period from recruitmentto 1year of age
|
Incidence of all episodes of malaria associated fevers…and the incidence of anaemia during the intermittent treatment phase (2–15 months) and after the effect of the intervention had ceased (16–23 months)
|
Same as protocol
|
Not clear whether the primary outcome was “first or single malaria episodes” or “cumulative episodes” or malaria
|
(1) The proportion of children with at least 1 episode of mild anemia and (2) the proportion of children with at least 1 episode of malaria between 3 and 18 months of age. Anemia was defined as Hb<8.0g/dL. Malaria was parasitemia with fever.
|
Incidences of all and of first or only episodes of malaria and severe anemia during the intervention period
|
|
Assumptions – protocol
|
Control group: 0.63 incidence clinical malaria/PYAR; 0.42 incidence severe malaria/PYAR; 30% reduction in SP
|
N/A
|
Placebo incidence rate = 0.33 case/yr
|
Assumptions not presented
|
Placebo proportions—anemia: 0.28; malaria: 0.60
|
Assumptions not presented
|
|
Assumptions-manuscript
|
Control group: 0.36 clinical malaria/PYAR; 0.28 episodes of severe malaria/PYAR
|
Incidence in placebo group 25%
|
Same as protocol
|
Assumptions not presented
|
Same as protocol for anemia; no mention of malaria
|
Assumptions not presented
|
|
Power-protocol
|
Protocol says “adequate”
|
N/A
|
80% power to detect a protective efficacy of 30% against having at least one episode of malaria
|
Power not in protocol. Method of analysis not clearly defined
|
80% to detect a protective efficacy of 30% against having at least one episode of anemiaand 16% for malaria
|
No power calculation
|
|
Power-manuscript
|
80%
|
95% power to detect a 25% reduction (cluster randomization)
|
Same as protocol
|
Study designed with 80% power to detect 20% reduction in “hazards of developing malaria in the SP group, compared with the placebo group”
|
Same as protocol for anemia; no mention of malaria
|
Sample size adequate to detect 25% reduction in malaria and severe anemia
|
|
NOTES: N/A = not available to the committee; PYAR = person years at risk.
SOURCE: Compiled from the trial protocols provided by the IPTi Consortium and the published manuscripts of the studies.
|